Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

  • REVIEW ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Immune checkpoint inhibitors (ICI) have changed the prognosis of many tumors. However, concerning associated cardiotoxicity has been reported. Little is known about the real-life incidence-specific surveillance protocols or the translational correlation between the underlying mechanisms and the clinical presentation of ICI-induced cardiotoxicity. The lack of data from prospective studies led us to review the current knowledge and to present the creation of the Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT), a prospective registry of patients receiving ICI that aims to examine the role of hsa-miR-Chr8:96, (a specific serum biomarker of myocarditis) in the early diagnosis of ICI-induced myocarditis. An exhaustive prospective cardiac imaging study will be performed before and during the first 12 months of treatment. The correlation between clinical, imaging, and immunologic parameters may improve our understanding of ICI-induced cardiotoxicity and enable simpler surveillance protocols. We assess ICI-induced cardiovascular toxicity and describe the rationale of the SIR-CVT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data Availability

There is no Data Availability Statement for this review.

References

  1. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, et al. Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis. Front Oncol. 2021;11:633032.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58.

    Article  CAS  PubMed  Google Scholar 

  4. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299–311.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. D’Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021;42(16):1621–31.

    Article  PubMed  Google Scholar 

  6. Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, Bechter O, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022;40(29):3430–8.

    Article  CAS  PubMed  Google Scholar 

  7. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.

    Article  CAS  PubMed  Google Scholar 

  8. Jiménez-Alejandre R, Ruiz-Fernández I, Martín P. Pathophysiology of immune checkpoint inhibitor-induced myocarditis. Cancers. 2022;14(18):4494.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res. 2021;128(11):1780–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cruz-Adalia A, Jiménez-Borreguero LJ, Ramírez-Huesca M, Chico-Calero I, Barreiro O, López-Conesa E, et al. CD69 limits the severity of cardiomyopathy after autoimmune myocarditis. Circulation. 2010;122(14):1396–404.

    Article  CAS  PubMed  Google Scholar 

  11. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361.

    Article  PubMed  Google Scholar 

  13. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zlotoff DA, Hassan MZO, Zafar A, Alvi RM, Awadalla M, Mahmood SS, et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021;9(3):e002007.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. 2020;75(5):467–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al. Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis. J Am Coll Cardiol. 2021;77(12):1503–16.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280–99.

    Article  PubMed  Google Scholar 

  19. Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: cardiooncology primer. JACC CardioOncol. 2021;3(1):35–47.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Blanco-Dominguez R, Sanchez-Diaz R, de la Fuente H, Jimenez-Borreguero LJ, Matesanz-Marin A, Relano M, et al. A Novel circulating microRNA for the detection of acute myocarditis. N Engl J Med. 2021;384(21):2014–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020;141(24):2031–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw. 2019;17(3):255–89.

    Article  CAS  PubMed  Google Scholar 

  23. Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M, et al. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. J Immunother Cancer. 2020;8(2):e001887.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Wang C, Lin J, Wang Y, Hsi DH, Chen J, Liu T, et al. Case series of steroid-resistant immune checkpoint inhibitor associated myocarditis: a comparative analysis of corticosteroid and Tofacitinib treatment. Front Pharmacol. 2021;12:770631.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085–7.

    Article  PubMed  Google Scholar 

  27. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al. Current state of knowledge on Takotsubo syndrome: a position statement from the taskforce on Takotsubo syndrome of the heart failure association of the european society of cardiology. Eur J Heart Fail. 2016;18(1):8–27.

    Article  PubMed  Google Scholar 

  28. Ederhy S, Dolladille C, Thuny F, Alexandre J, Cohen A. Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication. Eur J Heart Fail. 2019;21(7):945–7.

    Article  PubMed  Google Scholar 

  29. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Serzan M, Rapisuwon S, Krishnan J, Chang IC, Barac A. Takotsubo cardiomyopathy associated with checkpoint inhibitor therapy: endomyocardial biopsy provides pathological insights to dual diseases. JACC CardioOncol. 2021;3(2):330–4.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, et al. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9(6):e002771.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ma Z, Pei J, Sun X, Liu L, Lu W, Guo Q, et al. Pericardial toxicities associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2021;12:663088.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Saade A, Mansuet-Lupo A, Arrondeau J, Thibault C, Mirabel M, Goldwasser F, et al. Pericardial effusion under nivolumab: case-reports and review of the literature. J Immunother Cancer. 2019;7(1):266.

    Article  PubMed  Google Scholar 

  35. Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, et al. Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol. 2019;14(6):1102–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015;2015:794842.

    PubMed  PubMed Central  Google Scholar 

  37. Nykl R, Fischer O, Vykoupil K, Taborsky M. A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI)—Systemic inflammatory response syndrome after use of pembrolizumab. Arch Med Sci Atheroscler Dis. 2017;2:e100–2.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Investig. 2007;117(10):2974–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Matsumoto T, Sasaki N, Yamashita T, Emoto T, Kasahara K, Mizoguchi T, et al. Overexpression of cytotoxic T-lymphocyte–associated antigen-4 prevents atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2016;36(6):1141–51.

    Article  CAS  PubMed  Google Scholar 

  40. Poels K, Neppelenbroek SIM, Kersten MJ, Antoni ML, Lutgens E, Seijkens TTP. Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. J Immunother Cancer. 2021;9(6):e002916.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–42.

    Article  CAS  PubMed  Google Scholar 

  42. Majem M, García-Martínez E, Martinez M, Muñoz-Couselo E, Rodriguez-Abreu D, Alvarez R, et al. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clin Transl Oncol. 2020;22(2):213–22.

    Article  CAS  PubMed  Google Scholar 

  43. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80–91.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Health UDo, Services H. Common Terminology Criteria for Adverse Events. Version 5.0. Published November 27, 2017. 2020.

  45. Waliany S, Neal JW, Reddy S, Wakelee H, Shah SA, Srinivas S, et al. Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors. JACC CardioOncol. 2021;3(1):137–9.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23(10):1739–47.

    Article  CAS  PubMed  Google Scholar 

  47. Jain P, Gutierrez Bugarin J, Guha A, Jain C, Patil N, Shen T, et al. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO open. 2021;6(5):100252.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Mittendorf EA, Burgers F, Haanen J, Cascone T. Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease. Am Soc Clin Oncol Educ Book. 2022;42:189–203.

    Article  Google Scholar 

  49. Eggermont Alexander MM, Kicinski M, Blank Christian U, Mandala M, Long Georgina V, Atkinson V, et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid. 2022;1(11):EVIDoa2200214.

    Google Scholar 

  50. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–25.

    Article  CAS  PubMed  Google Scholar 

  52. Chitturi KR, Xu J, Araujo-Gutierrez R, Bhimaraj A, Guha A, Hussain I, et al. Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer. JACC. 2019;1(2):182–92.

    PubMed  PubMed Central  Google Scholar 

  53. Bar J, Markel G, Gottfried T, Percik R, Leibowitz-Amit R, Berger R, et al. Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. Eur J Cancer. 2019;120:122–31.

    Article  CAS  PubMed  Google Scholar 

  54. Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, et al. Factors associated with immune checkpoint inhibitor-related myocarditis. JAMA Oncol. 2019;5(11):1635–7.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Champion SN, Stone JR. Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod Pathol. 2020;33(1):99–108.

    Article  CAS  PubMed  Google Scholar 

  56. Cautela J, Rouby F, Salem JE, Alexandre J, Scemama U, Dolladille C, et al. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can J Cardiol. 2020;36(4):476–81.

    Article  PubMed  Google Scholar 

  57. Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020;8(1):e000261.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Finke D, Heckmann MB, Herpel E, Katus HA, Haberkorn U, Leuschner F, et al. Early detection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET/CT. Front Cardiovasc Med. 2021. https://doi.org/10.3389/fcvm.2021.614997.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021;23(10):1725–35.

    Article  CAS  PubMed  Google Scholar 

  60. Waheed N, Fradley MG, DeRemer DL, Mahmoud A, Shah CP, Langaee TY, et al. Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardiooncology. 2021;7(1):10.

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

The funding was provided by Ministerio de Ciencia e Innovación. Award number: PMPTA22/00090; Grant Recipient: Pilar Martin. Instituto de Salud Carlos III. Award number: PI22/01759. Grant recipient: Pilar Martin.

Author information

Authors and Affiliations

  1. Cardiology Department, Hospital General Universitario Gregorio Marañón, CIBER-CV (Instituto de Salud Carlos III), Universidad Complutense, Madrid, Spain

    Eduardo Zatarain-Nicolás

  2. Centro Nacional de Investigaciones Cardiovasculares (CNIC), CIBER-CV (Instituto de Salud Carlos III), Madrid, Spain

    Pilar Martín

  3. Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Iván Márquez Rodas

  4. Medical Oncology Department, Hospital Universitario Virgen de la Macarena, Seville, Spain

    Juan Virizuela

  5. Cardiology Department, Complejo Asistencial Universitario de Salamanca, IBSAL, USAL, CIBER-CV (Instituto de Salud Carlos III), Salamanca, Spain

    Ana Martín García

  6. Cardiology Department, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBER-CV (Instituto de Salud Carlos III), Madrid, Spain

    Cristina Mitroi

  7. Agencia de Investigación de la Sociedad Española de Cardiología (AISEC), Madrid, Spain

    Juan Cosín Sales & Vivencio Barrios

  8. Cardiology Department, Hospital Arnau de Vilanova, Universidad CEU-Cardenal Herrera, Valencia, Spain

    Juan Cosín Sales

  9. Cardiology Department, Hospital Universitario Ramon y Cajal, Universidad de Alcalá, Madrid, Spain

    Vivencio Barrios

  10. Bioinformatics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC), CIBER-CV (Instituto de Salud Carlos III), Madrid, Spain

    Fátima Sánchez-Cabo

  11. Cardiology Department, IIS-Fundación Jiménez Díaz University Hospital, CIBER-CV (Instituto de Salud Carlos III), CNIC, Madrid, Spain

    Borja Ibañez

  12. Medical Oncology Department, La Paz University Hospital, Madrid, Spain

    Javier de Castro Carpeño

  13. Cardiology Service, Cardio-Oncology Unit, La Paz University Hospital and IdiPAz Research Institute, Madrid, Spain

    Teresa López Fernández

Authors
  1. Eduardo Zatarain-Nicolás
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pilar Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iván Márquez Rodas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan Virizuela
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ana Martín García
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cristina Mitroi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Juan Cosín Sales
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vivencio Barrios
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fátima Sánchez-Cabo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Borja Ibañez
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Javier de Castro Carpeño
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Teresa López Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Eduardo Zatarain-Nicolás or Teresa López Fernández.

Ethics declarations

Conflict of interest

Every author has communicate his/her conflicts of interest.

Ethical approval (Research involving human participants and/or animals), Informed consent

The study protocol has been approved by the ethical committee at Hospital General Universitario Gregorio Marañón and accomplish with the Declaration of Helsinki and current legislation.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 17 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zatarain-Nicolás, E., Martín, P., Márquez Rodas, I. et al. Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity. Clin Transl Oncol 25, 3073–3085 (2023). https://doi.org/10.1007/s12094-023-03217-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-023-03217-2

Keywords

Search

Navigation